Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-21

FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental NDA for a generic calcipotriene and betamethasone dipropionate topical product from Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Calcipotriene and Betamethasone Dipropionate (Calcipotriene and Betamethasone Dipropionate)

Snippet

SUPPL AP for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)